SEC Filing Summary: Synaptogenix, Inc. (SNPX) - Form 10-Q
Business Context and Reporting Period
This summary covers the quarterly report (Form 10-Q) for Synaptogenix, Inc. (SNPX) for the period ended June 30, 2024. Synaptogenix is a biopharmaceutical company focused on developing Bryostatin-1 for Alzheimer's disease (AD) and other neurodegenerative disorders. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. Notably, the company effected a 1-for-25 reverse stock split on April 4, 2024, to regain compliance with Nasdaq listing requirements; all share data in this report is retroactively adjusted.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | $0 (No product revenue) | $0 |
| Net Loss | $(1,480,008) | $(5,805,738) |
| Net Loss Attributable to Common Stockholders | $(1,854,202) | $(12,188,387) |
| Operating Expenses | $3,272,461 | $4,751,654 |
| Other Income (Loss) | $1,792,453 | $(1,054,084) |
| Cash and Cash Equivalents (End of Period) | $24,976,423 | $32,899,410 |
| Working Capital | $18,472,861 | $26,256,291 |
| Total Liabilities | $9,588,612 | $5,529,469 |
| Accrued Series B Preferred Payments | $8,829,761 | $3,395,945 |
Note: The company generated $793,903 in interest income for the six months ended June 30, 2024.
Material Changes vs. Prior Period
- Reduced Net Loss: Net loss decreased by approximately 74.5% year-over-year, primarily driven by a significant reduction in operating expenses and a swing in "Other Income" from a loss to a gain.
- Operating Expense Reduction: Total operating expenses declined by 31.1% to $3.27 million. This was due to lower Research and Development (R&D) costs ($951k vs $1.18M) and General and Administrative (G&A) costs ($2.32M vs $3.57M). The decrease in R&D reflects the conclusion of the Phase 2 AD trial in late 2023 and the discontinuation of a dose-ranging study, partially offset by the initiation of a Multiple Sclerosis (MS) trial.
- Other Income Volatility: Other income improved by over $3 million, turning from a loss of $1.05M to a gain of $1.79M. This was largely due to a $1.11M gain from the change in fair value of a derivative liability (which was extinguished) and interest income, offset by a $96k loss on warrant liability fair value changes.
- Liability Increase: Total liabilities increased by $4.06M, driven primarily by the accrual of Series B Convertible Preferred Stock redemption payments and dividends, which rose from $3.4M to $8.8M.
- Preferred Stock Redemption: During the period, the company redeemed $6 million of Series B Preferred Stock and $122,500 of accrued dividends by issuing 274,219 shares of Common Stock.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects current cash reserves of approximately $24.4 million to be sufficient to fund operations for at least the next 12 months. However, additional capital will be required to complete clinical trials and pursue regulatory approval.
- Clinical Development:
- Alzheimer's Disease: The Phase 2 confirmatory study (Study #204) was completed in December 2023 but did not achieve statistical significance on the primary endpoint. Secondary endpoints showed significance in the most severe patient subgroup (MMSE 10-14).
- Multiple Sclerosis (MS): A Phase 1 trial with Cleveland Clinic is underway. Cumulative expenses incurred are approximately $590,000.
- Fragile X: An IND has been filed with the FDA but is currently on clinical hold pending further pharmacokinetic and pharmacodynamic analytics.
- Spinal Cord Injury: A new collaboration with LSU Health was signed in June 2024 to test PUFA analogs.
- Key Risks:
- Capital Constraints: Future financing may be dilutive or unavailable. The company has significant accrued liabilities related to Series B Preferred Stock.
- Internal Controls: The company disclosed that its disclosure controls and procedures are not effective due to material weaknesses, including inadequate segregation of duties, ineffective financial reporting processes, and weak IT general controls.
- Supply Chain: Reliance on the National Cancer Institute (NCI) and third-party suppliers for bryostatin supply poses a risk to clinical trial continuity.
Investor Verification Checklist
- Verify Liquidity Runway: Confirm the $24.4M cash balance against the projected burn rate, considering the $8.8M accrued liability for Series B Preferred Stock redemptions.
- Review Internal Control Remediation: Assess the company's plan to address the material weaknesses in internal controls over financial reporting disclosed in Item 4.
- Monitor Clinical Holds: Track the status of the FDA clinical hold on the Fragile X IND and the timeline for resolution.
- Check Preferred Stock Terms: Review the specific terms of the Series B Preferred Stock redemption schedule and the potential for further dilution via share-settled payments.
- Validate Revenue Assumptions: Note that the company has no product revenue; all future value is contingent on successful clinical outcomes and regulatory approval.